351 related articles for article (PubMed ID: 31714962)
1. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.
Huang QS; Wang JZ; Qin YZ; Zeng QZ; Jiang Q; Jiang H; Lu J; Liu HX; Liu Y; Wang JB; Su L; Zhang HY; Li ZL; Gao SJ; Huang B; Liu YY; Liu YR; Xu LP; Huang XJ; Zhang XH
Blood Adv; 2019 Nov; 3(21):3406-3418. PubMed ID: 31714962
[TBL] [Abstract][Full Text] [Related]
2. [Expression of WT1 and PRAME gene in bone marrow and peripheral blood samples of patients with myelodysplastic syndrome].
Lu D; Qin YZ; Li LD; Shi HX; Lai YY; Liu YR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):370-6. PubMed ID: 24763007
[TBL] [Abstract][Full Text] [Related]
3. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes.
Qin YZ; Zhu HH; Liu YR; Wang YZ; Shi HX; Lai YY; Xu LP; Liu DH; Jiang Q; Li LD; Jiang B; Liu KY; Huang XJ
Leuk Lymphoma; 2013 Jul; 54(7):1442-9. PubMed ID: 23110703
[TBL] [Abstract][Full Text] [Related]
4. Wilms Tumor 1 (WT1) mRNA Expression Level at Diagnosis Is a Significant Prognostic Marker in Elderly Patients with Myelodysplastic Syndrome.
Nagasaki J; Aoyama Y; Hino M; Ido K; Ichihara H; Manabe M; Ohta T; Mugitani A
Acta Haematol; 2017; 137(1):32-39. PubMed ID: 27866185
[TBL] [Abstract][Full Text] [Related]
5. High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
Shiseki M; Ishii M; Ohwashi M; Wang YH; Tanaka N; Osanai S; Yoshinaga K; Mori N; Tanaka J
Leuk Lymphoma; 2021 Oct; 62(10):2448-2456. PubMed ID: 34013846
[TBL] [Abstract][Full Text] [Related]
6. Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.
Minetto P; Guolo F; Clavio M; De Astis E; Colombo N; Grasso R; Fugazza G; Sessarego M; Lemoli RM; Gobbi M; Miglino M
Leuk Res; 2015 Aug; 39(8):866-73. PubMed ID: 26012361
[TBL] [Abstract][Full Text] [Related]
7. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
8. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML).
Steger B; Floro L; Amberger DC; Kroell T; Tischer J; Kolb HJ; Schmetzer HM
J Immunother; 2020; 43(6):204-215. PubMed ID: 32502139
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Mo XD; Qin YZ; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
Ann Hematol; 2016 Aug; 95(8):1233-40. PubMed ID: 27302479
[TBL] [Abstract][Full Text] [Related]
10. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
Cilloni D; Gottardi E; Messa F; Fava M; Scaravaglio P; Bertini M; Girotto M; Marinone C; Ferrero D; Gallamini A; Levis A; Saglio G;
J Clin Oncol; 2003 May; 21(10):1988-95. PubMed ID: 12743153
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Kobayashi S; Ueda Y; Nannya Y; Shibayama H; Tamura H; Ogata K; Akatsuka Y; Usuki K; Ito Y; Okada M; Suzuki T; Hata T; Matsuda A; Tohyama K; Kakumoto K; Koga D; Mitani K; Naoe T; Sugiyama H; Takaku F
Cancer Biomark; 2016 Mar; 17(1):21-32. PubMed ID: 27062571
[TBL] [Abstract][Full Text] [Related]
12. Associations between the peripheral blood Wilms tumor gene 1 level and both bone marrow blast cells and the prognosis in patients with myelodysplastic syndrome.
Mashima K; Ikeda T; Toda Y; Ito S; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Fujiwara S; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Leuk Lymphoma; 2019 Mar; 60(3):703-710. PubMed ID: 30188227
[TBL] [Abstract][Full Text] [Related]
13. Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.
Pan D; Zhao W; Jiang Q; Yin C; He H; Liao L; Ye J; Dai M
Leuk Lymphoma; 2023 Apr; 64(4):856-864. PubMed ID: 36905177
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival.
Santamaría C; Ramos F; Puig N; Barragán E; de Paz R; Pedro C; Insunza A; Tormo M; Del Cañizo C; Diez-Campelo M; Xicoy B; Salido E; Sánchez del Real J; Hernández M; Chillón C; Sanz GF; García-Sanz R; San Miguel JF; González M
Ann Hematol; 2012 Dec; 91(12):1887-95. PubMed ID: 22875062
[TBL] [Abstract][Full Text] [Related]
15. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.
Ueda Y; Mizutani C; Nannya Y; Kurokawa M; Kobayashi S; Takeuchi J; Tamura H; Ogata K; Dan K; Shibayama H; Kanakura Y; Niimi K; Sasaki K; Watanabe M; Emi N; Teramura M; Motoji T; Kida M; Usuki K; Takada S; Sakura T; Ito Y; Ohyashiki K; Ogawa H; Suzuki T; Ozawa K; Imai K; Kasai M; Hata T; Miyazaki Y; Morita Y; Kanamaru A; Matsuda A; Tohyama K; Koga D; Tamaki H; Mitani K; Naoe T; Sugiyama H; Takaku F
Leuk Lymphoma; 2013 Jul; 54(7):1450-8. PubMed ID: 23110324
[TBL] [Abstract][Full Text] [Related]
17. [Wilms' tumor-1 gene expression in myelodysplastic syndrome and its changes in the process of myelodysplastic syndrome transforming into acute leukemia].
Yang JK; Li JL; Li ZG; Li ZG; Liu PJ; Li JY; Lü HR; Deng Q; Lin XM; Cao JN
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2003 Sep; 15(9):557-9. PubMed ID: 12971856
[TBL] [Abstract][Full Text] [Related]
18. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
19. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database.
Voso MT; Fenu S; Latagliata R; Buccisano F; Piciocchi A; Aloe-Spiriti MA; Breccia M; Criscuolo M; Andriani A; Mancini S; Niscola P; Naso V; Nobile C; Piccioni AL; D'Andrea M; D'Addosio A; Leone G; Venditti A
J Clin Oncol; 2013 Jul; 31(21):2671-7. PubMed ID: 23796988
[TBL] [Abstract][Full Text] [Related]
20. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index.
van Spronsen MF; Ossenkoppele GJ; Holman R; van de Loosdrecht AA
Eur J Cancer; 2014 Dec; 50(18):3198-205. PubMed ID: 25454415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
